MA33244B1 - Composes de vinylindazolyle - Google Patents

Composes de vinylindazolyle

Info

Publication number
MA33244B1
MA33244B1 MA34312A MA34312A MA33244B1 MA 33244 B1 MA33244 B1 MA 33244B1 MA 34312 A MA34312 A MA 34312A MA 34312 A MA34312 A MA 34312A MA 33244 B1 MA33244 B1 MA 33244B1
Authority
MA
Morocco
Prior art keywords
vinylindazolyl
compounds
indazolyl
cancer
treatment
Prior art date
Application number
MA34312A
Other languages
English (en)
Inventor
Daohong Chen
Hong-Yu Li
Genshi Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33244B1 publication Critical patent/MA33244B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur des composés vinyl indazolylés utiles dans le traitement du cancer.
MA34312A 2009-05-07 2010-05-04 Composes de vinylindazolyle MA33244B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17629009P 2009-05-07 2009-05-07
US30141610P 2010-02-04 2010-02-04
PCT/US2010/033487 WO2010129509A1 (fr) 2009-05-07 2010-05-04 Composés vinyl indazolylés

Publications (1)

Publication Number Publication Date
MA33244B1 true MA33244B1 (fr) 2012-05-02

Family

ID=42238704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34312A MA33244B1 (fr) 2009-05-07 2010-05-04 Composes de vinylindazolyle

Country Status (34)

Country Link
US (1) US8268869B2 (fr)
EP (1) EP2427449B1 (fr)
JP (1) JP5555314B2 (fr)
KR (1) KR101373910B1 (fr)
CN (1) CN102421769B (fr)
AR (1) AR078411A1 (fr)
AU (1) AU2010246114B2 (fr)
BR (1) BRPI1013748A2 (fr)
CA (1) CA2760535C (fr)
CL (1) CL2011002781A1 (fr)
CO (1) CO6450624A2 (fr)
CR (1) CR20110580A (fr)
DK (1) DK2427449T3 (fr)
EA (1) EA018149B1 (fr)
EC (1) ECSP11011441A (fr)
ES (1) ES2408117T3 (fr)
HN (1) HN2011002809A (fr)
HR (1) HRP20130323T1 (fr)
IL (1) IL216004A (fr)
JO (1) JO2860B1 (fr)
MA (1) MA33244B1 (fr)
ME (1) ME01462B (fr)
MX (1) MX2011011342A (fr)
MY (1) MY160390A (fr)
NZ (1) NZ595553A (fr)
PE (2) PE20160124A1 (fr)
PL (1) PL2427449T3 (fr)
PT (1) PT2427449E (fr)
RS (1) RS52795B (fr)
SG (1) SG175909A1 (fr)
SI (1) SI2427449T1 (fr)
TW (1) TWI382982B (fr)
UA (1) UA104756C2 (fr)
WO (1) WO2010129509A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
BR112014021897B1 (pt) 2012-03-08 2022-06-14 Astellas Pharma Inc Método, kit, conjunto de iniciadores e conjuntos de sondas para detectar um gene de fusão composto por um gene fgfr3 e um gene tacc3
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2968551B1 (fr) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Protéines de fusion et procédés correspondants
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3237452A4 (fr) 2014-12-23 2018-12-05 The Trustees of Columbia University in the City of New York Protéines de fusion et procédés associés
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
WO2016187767A1 (fr) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Compositions pharmaceutiques et utilisation de celles-ci
JP6898306B2 (ja) * 2015-08-07 2021-07-07 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
JP6549311B2 (ja) 2015-08-20 2019-07-24 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． インドール誘導体、その調製方法および医薬におけるその使用
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4056558A4 (fr) * 2019-11-06 2023-12-27 Jinan University Composé d'indazole, composition pharmaceutique de celui-ci et ses applications
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021113462A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Dérivés d'un inhibiteur de fgfr
WO2021138391A1 (fr) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7511294B2 (ja) * 2020-08-11 2024-07-05 ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド Ｆｇｆｒ阻害剤化合物及びその使用
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
CN116554148B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种乙烯基吲唑类氘代fgfr抑制剂药物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
WO2003033472A1 (fr) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
KR20050004214A (ko) * 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
WO2005116027A2 (fr) 2004-05-26 2005-12-08 Pfizer Limted Nouveaux derives indazole et indolone et leur utilisation pharmaceutique
WO2007058626A1 (fr) 2005-11-16 2007-05-24 S*Bio Pte Ltd Composes d'indazole
WO2007067537A1 (fr) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Composés inhibant les pyrrolopyridine kinases
EP2120932B1 (fr) 2006-12-20 2014-07-09 Nerviano Medical Sciences S.r.l. Dérivés de l'indazole en tant qu'inhibiteurs des kinases pour le traitement du cancer
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
AR068046A1 (es) 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
EP2265270A1 (fr) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. Inhibiteurs de 2-aminopyridine kinases

Also Published As

Publication number Publication date
JP5555314B2 (ja) 2014-07-23
PE20120812A1 (es) 2012-07-08
KR20120004511A (ko) 2012-01-12
JO2860B1 (en) 2015-03-15
UA104756C2 (uk) 2014-03-11
PT2427449E (pt) 2013-05-06
EA018149B1 (ru) 2013-05-30
NZ595553A (en) 2013-05-31
RS52795B (sr) 2013-10-31
HRP20130323T1 (en) 2013-05-31
EP2427449A1 (fr) 2012-03-14
PE20160124A1 (es) 2016-02-24
SG175909A1 (en) 2011-12-29
DK2427449T3 (da) 2013-04-22
MY160390A (en) 2017-03-15
ME01462B (me) 2014-04-20
IL216004A0 (en) 2012-01-31
CA2760535A1 (fr) 2010-11-11
TWI382982B (zh) 2013-01-21
AU2010246114A1 (en) 2011-11-03
CN102421769B (zh) 2014-04-02
TW201105652A (en) 2011-02-16
BRPI1013748A2 (pt) 2016-04-05
AR078411A1 (es) 2011-11-09
WO2010129509A1 (fr) 2010-11-11
HN2011002809A (es) 2013-07-22
JP2012526126A (ja) 2012-10-25
US20100286209A1 (en) 2010-11-11
AU2010246114B2 (en) 2012-12-06
SI2427449T1 (sl) 2013-05-31
PL2427449T3 (pl) 2013-08-30
CO6450624A2 (es) 2012-05-31
EA201171367A1 (ru) 2012-04-30
EP2427449B1 (fr) 2013-04-03
IL216004A (en) 2014-01-30
ECSP11011441A (es) 2011-12-30
US8268869B2 (en) 2012-09-18
CL2011002781A1 (es) 2012-05-25
KR101373910B1 (ko) 2014-03-12
CN102421769A (zh) 2012-04-18
HK1163665A1 (en) 2012-09-14
MX2011011342A (es) 2011-11-18
ES2408117T3 (es) 2013-06-18
CA2760535C (fr) 2014-01-14
CR20110580A (es) 2012-01-06

Similar Documents

Publication Publication Date Title
JO2860B1 (en) Phenylendazolyl compounds
EP2482849A4 (fr) Immunothérapie combinée pour le traitement du cancer
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
EP2391316A4 (fr) Traitement de l'obésité
EP2555765A4 (fr) Traitement de l'ataxie télangiectasie
MX364200B (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EP2542081A4 (fr) Composés destinés au traitement du cancer
EP2389388A4 (fr) Traitement de l'obésité
EP2493820A4 (fr) Traitement de l'eau
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
EP2496244A4 (fr) Immunothérapie pharmacorésistante pour le traitement d'un cancer
PH12012501542A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensis
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MA32617B1 (fr) Traitement de l'hypertension arterielle pulmonaire
EP2582391A4 (fr) Traitement de l'arthrite
IN2012DN00539A (fr)
MY151104A (en) Novel use
EP2608671A4 (fr) Composés utilisés dans le traitement du cancer
EP2517095A4 (fr) Traitement de recouvrements
EP2758134A4 (fr) Buprénorphine pour le traitement d'une tendance suicidaire aiguë
GB0904427D0 (en) Treatment of diseases related to hyperactivity of the complement system
EP2274245A4 (fr) Phytosystème destiné au traitement des eaux usées
EP2544686A4 (fr) Procédés combinés pour le traitement de maladies
EP2437738A4 (fr) Procédés et compositions pour le traitement du cancer